Literature DB >> 17941358

Common and alternate oral antibiotic therapies for acne vulgaris: a review.

Kathani Amin1, Christy C Riddle, Daniel J Aires, Eric S Schweiger.   

Abstract

Acne vulgaris is an extremely common disorder affecting many adolescents and adults throughout their lifetimes. The pathogenesis of acne is multifactorial and is thought to involve excess sebum, follicular hyperkeratinization, bacterial colonization, and inflammation. Many therapeutic options exist for treating acne, including topical benzoyl peroxide, topical and oral antibiotics, topical and oral retinoids, and oral contraceptives. Oral antibiotics have been a mainstay in the treatment of acne for decades and function by exerting an antibacterial effect by reducing the follicular colonization of Propionibacterium acnes. Systemic antibiotics also have anti-inflammatory and immunomodulatory properties. This article reviews the English language literature on the efficacy of various systemic antibiotics for treating acne vulgaris, including second-line and less historically used medications. We discuss the tetracyclines, including subantimicrobial dose doxycycline, macrolides (notably azithromycin), trimethoprim-sulfamethoxazole, cephalosporins, and fluoroquinolones as treatment options for acne vulgaris.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941358

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

Review 1.  Oral Antibiotics for Acne.

Authors:  Dillon J Patel; Neal Bhatia
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 7.403

2.  Propionibacterium acnes infections in patients with idiopathic scoliosis: a case-control study and review of the literature.

Authors:  I Swarup; J Gruskay; M Price; J Yang; J Blanco; S Perlman; R Widmann
Journal:  J Child Orthop       Date:  2018-04-01       Impact factor: 1.548

3.  Oesophageal ulceration in adult patients treated with doxycycline for acne vulgaris.

Authors:  Yan Guo; Hua-Ming Li; Chun-Xia Li; Wei-Qin Zhu; Yu-Fang Wang; Ya-Hong He
Journal:  J Int Med Res       Date:  2019-11-10       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.